HeartMate 3 LVAD Patient Education
Patients with advanced heart failure may not fully grasp that heart failure is a serious, progressive disease. They may not realize how sick they truly are until it’s too late.
You can help your patients understand if HeartMate 3™ LVAD therapy might be a treatment option before their heart failure progresses, giving them more time to decide and plan for their heart failure treatment.
Here are a few points you might want to share with your patients:
- LVAD therapy is an option for patients with NYHA Class IIIB-IV heart failure
- HeartMate 3 LVAD is a small implantable pump that is designed to help their heart pump blood
- There have been significant clinical advancements in LVAD therapy, with HeartMate 3 LVAD survival rate now comparable to heart transplant at 2 years1,2*
- HeartMate 3 LVAD has an excellent safety profile, with reduced stroke and pump thrombosis adverse events rates3
Access ongoing support for informed conversations about advanced heart failure and LAVD therapy.
Resources to Support LVAD Patient Education & Discussion
Live a More Active Life with an LVAD
Review fast facts and helpful information about living life with a HeartMate 3 LVAD.
HeartMate 3 Left Ventricular Assist Device (LVAD) Patient Guide
This patient guide is for using the HeartMate 3 LVAD that both the patient and caregiver will need to be familiar with upon hospital discharge.
HeartMate 3 LVAD Patient Education Handbook
This guide, created by the Advanced Cardiac Therapies Improving Outcomes Network (ACTION), is an easy-to-read education reference and scrapbook for patients to use on their LVAD journey.
HeartMate 3 LVAD Pediatric Patient Education Handbook
This pediatric handbook is a guide for young patients co-created with the Advanced Cardiac Therapies Improving Outcomes (ACTION) Network to help them navigate their LVAD journey.
Patient Education videos for understanding the HeartMate 3 LVAD pre-implant and post-implant.
*Based on published data from separate datasets, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.
References
- Teuteberg JJ, Cleveland JC, Cowger J, Higgins RS, et al. The Society of Thoracic Surgeons Intermacs 2019 Annual Report: the changing landscape of devices and indications. Ann Thorac Surg. 2020;109:649-660.
- Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplant Report-2018: Focus Theme: Multiorgan Transplantation. J Heart Lung Transplant 2018:37:1155-1168.
- Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. JAMA. September 8, 2022.
MAT-2642385 v10.0